1. Scrip
  2. >>Archive

Small Steps Forward in Treating Ischemic Stroke

 
• By Wendy Diller

Stroke remains a devastating disease that isn't adequately addressed, but the pharmaceutical industry remains wary of the field, having been stung in the past by extremely expensive clinical disappointments. Nevertheless, the opportunity is too enticing for the industry to ignore completely. Two pharma-sponsored major clinical trials are underway for treatment of acute ischemic stroke, foro example. The emerging companies with stroke therapies profiled here, however, are cautiously pushing forward on several fronts, of which the stroke market may or not be the first and foremost application of core technology.

The FDA's recent approval of Concentric Medical Inc. 's device for retrieving clots in some ischemic stroke victims is good news for a field that offers few treatment options. (See "Concentric's Clearance Not Likely to Spur Stroke Investment," START-UP, September 2004 Also see "Concentric's Clearance Not Likely to Spur Stroke Investment" - Medtech Insight, 1 September, 2004..)

Until Concentric's Merci Retrieval device, the only FDA-approved method of breaking up brain clots had been administration of Genentech Inc....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.